PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial
Open Access
- 22 October 2010
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 376 (9749), 1329-1337
- https://doi.org/10.1016/s0140-6736(10)61086-0
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in WomenScience, 2010
- Assessing the Accuracy of Adherence and Sexual Behaviour Data in the MDP301 Vaginal Microbicides Trial Using a Mixed Methods and Triangulation ModelPLOS ONE, 2010
- A Mixed Methods and Triangulation Model for Increasing the Accuracy of Adherence and Sexual Behaviour Data: The Microbicides Development ProgrammePLOS ONE, 2010
- A randomised placebo-controlled safety and acceptability trial of PRO 2000 vaginal microbicide gel in sexually active women in UgandaSexually Transmitted Infections, 2010
- Postcoital Bioavailability and Antiviral Activity of 0.5% PRO 2000 Gel: Implications for Future Microbicide Clinical TrialsPLOS ONE, 2010
- Microbicides Development Programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV preventionTrials, 2009
- International consultation on the criminalization of HIV transmissionReproductive Health Matters, 2009
- Effectiveness of Cellulose Sulfate Vaginal Gel for the Prevention of HIV Infection: Results of a Phase III Trial in NigeriaPLOS ONE, 2008
- The role of partnership dynamics in determining the acceptability of condoms and microbicidesAIDS Care, 2008
- SAVVY Vaginal Gel (C31G) for Prevention of HIV Infection: A Randomized Controlled Trial in NigeriaPLOS ONE, 2008